Neville Rodie & Shaw Inc. decreased its position in Allergan PLC. (NYSE:AGN) by 12.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,699 shares of the company’s stock after selling 375 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Allergan PLC. were worth $656,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. GWM Advisors LLC boosted its stake in Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after buying an additional 5 shares in the last quarter. Burns J W & Co. Inc. NY boosted its stake in Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after buying an additional 6 shares in the last quarter. Trust Co boosted its stake in Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after buying an additional 10 shares in the last quarter. JNBA Financial Advisors boosted its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Finally, Tarbox Group Inc. boosted its stake in Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock worth $572,000 after buying an additional 15 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 0.32% during midday trading on Monday, hitting $233.63. 510,883 shares of the stock were exchanged. The company has a market capitalization of $78.10 billion, a P/E ratio of 7.12 and a beta of 1.16. The company’s 50 day moving average is $245.93 and its 200 day moving average is $238.13. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the company earned $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. Analysts predict that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. Allergan PLC.’s payout ratio is presently 9.95%.

WARNING: “Neville Rodie & Shaw Inc. Reduces Stake in Allergan PLC. (AGN)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/neville-rodie-shaw-inc-reduces-stake-in-allergan-plc-agn/1487537.html.

A number of analysts have recently issued reports on the stock. UBS AG restated a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research note on Monday, May 15th. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a research report on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price target (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Argus reaffirmed a “buy” rating and set a $280.00 price target on shares of Allergan PLC. in a research report on Monday. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research report on Wednesday, May 10th. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Allergan PLC. currently has an average rating of “Buy” and an average price target of $275.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is owned by company insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.